← All indications
Rubella
An acute infectious disease caused by the RUBELLA VIRUS. The virus enters the respiratory tract via airborne droplet and spreads to the LYMPHATIC SYSTEM.
Subtype terms (1)
More specific conditions that are subtypes of Rubella in the MeSH hierarchy.
- Rubella Syndrome, Congenital
1 drug approved
Drugs by status
Approved for this indication (5)
Phase 4 trials (8)
Phase 3 trials (13)
- albumin (Human)
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- Measles, Mumps and Rubella Vaccine, Live
- typhoid vi polysaccharide vaccine
- yellow fever vaccine 17d strain
- Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant)
- live attenuated varicella vaccine
- killed oral cholera vaccine
- pneumococcal 7-valent conjugate vaccine
- v221
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
Phase 1 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (26)
- Merck
- Sanofi
- Sanofi-Aventis
- GlaxoSmithKline
- INC Research
- PT Bio Farma
- Centers for Disease Control and Prevention, China
- Pan American Health Organization
- Maastricht University
- University of Groningen
- Utrecht University
- Assiut University
- University of Copenhagen
- Free University of Amsterdam
- International Center for Diarrheal Disease Research
- Government of China
- University of Paris
- Erasmus University Rotterdam
- Government of Bangladesh
- Beijing Tiantan Bio Co., Ltd
- Government of Argentina
- Centers for Disease Control and Prevention (CDC)
- Airlangga University
- PATH
- Oswaldo Cruz Foundation
- DF/Net Research
Organization Involved with Phase 2 Indications (6)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (3)